HomeSubscribeLogin
HomeLogout

ValuentumAd

Official PayPal Seal













Apr 6, 2018
Dividend Increases/Decreases for the Week Ending April 6
Let's take a look at companies that raised/lowered their dividend this week.
Apr 5, 2018
Walgreens Boots Alliance Remains at the Crossroads of a Rapidly-Evolving Healthcare Landscape
Image Source: Walgreens 2Q 2018 Earnings Release. The evolving healthcare landscape has been dealing with the threat of a disruptive new competitor entering the market and considerable political risk. Though the need for healthcare remains impervious to economic forces, a clear deflationary trend has descended on the industry that has affected many of the well-entrenched participants. Let’s examine Walgreens Boots Alliance for clues that a shift in sentiment may have occurred in this well known, yet beleaguered sector.
Mar 29, 2018
Verint’s Big Move Puts It Ahead of the Market
We think Verint Systems is getting a bad rap about its non-GAAP reporting. Operating cash flow at the company is tremendous, and the market may finally be coming around to recognizing its undervalued nature.
Mar 29, 2018
Dividend Highlights in Big Pharma
The first quarter of 2018 will go down in the record books as one of the most volatile in recent memory--a sharp jump out of the gate was met with significant selling at the end of March as numerous political and economic worries entered the picture. We believe a timely review of some of the dividend stalwarts is in order.
Mar 28, 2018
PCSK9 Woes Weigh on Amgen and Regeneron
Image shown: Amgen and Regeneron have both meaningfully trailed the market since October of 2017. The robustness of the clinical pipeline offers an important clue regarding the health and vitality of a biotech/pharma company, as the clinical pipeline is critical towards maintaining and growing the top line. One of the most promising, and dare-we-say, overhyped new treatments to enter the market is the PCSK9 cholesterol-lowering agents, with Amgen and Regeneron leading the pack. Let’s discuss the results of Regeneron’s treatment along with a discussion of the path forward for the treatment.
Mar 26, 2018
Ongoing Optimization To Maximize The Value
We continue to help readers find some of our best ideas for consideration, and companies in the Diagnostic Substances industry weren't well-traveled by our readership. We’re allocating resources to better and more compelling opportunities that maximize the value of your membership. Please be sure to access the simulated newsletter portfolios for our best ideas!
Mar 24, 2018
Archive: Nelson's "Off the Cuff" Video Series
Image: President of Investment Research Brian Nelson. We hope you enjoyed the "Off the Cuff" video series, where President of Investment Research at Valuentum Brian Nelson talked in front of the camera for about 10 minutes each episode! The videos were purposely designed to be low-tech, we know - we call this "authen-tech." We like that, and you should, too. These are not instructional videos. They are meant to be energetic, exciting, and a bit controversial. Nelson tells it how it is. That's the only way. Videos filmed December and January 2017/2018. Follow up reading/videos provided.
Mar 22, 2018
Trump Targets China with Tariffs
Image: Shanghai, China (December 2016), Andrey Filippov. Stock markets in the US are slowly building in the prospect of retaliation (a “trade war”) from China, as a result of President Trump’s new tariffs. We maintain our view that the stock market has been frothy for some time, and the recent volatility may just be the beginning of a reversion to normalized valuations, with or without concerns about global trade.
Mar 22, 2018
AbbVie’s Product Concentration Risk Intensifies; Shares Yield ~3.9%
AbbVie will not seek accelerated approval for what had been expected to be its next blockbuster drug, Rova-T, which had been investigated for third-line relapsed/refractory small cell lung cancer. The market is reacting negatively to the disappointment.
Mar 21, 2018
General Mills' Dividend Is Now of Questionable Health
General Mills is stuck between a rock and a hard place, and the market is finally noticing. Its best dividend growth years have been behind it, but its recent dealings have put it in a rather precarious position heading into the next recession, the timing of which is the only uncertainty. The company has never been a consideration for inclusion in the simulated Dividend Growth Newsletter portfolio.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.